Ludwig Cancer Research has chosen Lausanne as one of its main international sites and intends to invest more than CHF 100 million over the next ten years on applied cancer immunology and the design of novel molecular and cell-based immunotherapies, under a framework agreement with the Canton of Vaud covering a 30-year timescale.
“We are very enthusiastic about opening a Ludwig Branch in Lausanne,” said Edward Mc Dermott, CEO of Ludwig, in a press release. “We were greatly impressed by the scope and depth of scientific and IT expertise to be found there, not only in its academic institutions, but also in its biotech firms. I’m convinced that our partnership will be of immense benefit to cancer patients everywhere.”
Ludwig Lausanne will be based at the University of Lausanne (UNIL) and the Lausanne University Hospital (CHUV), and will operate in close collaboration with the new Swiss Cancer Center Lausanne (SCCL). The new branch will also work closely with Geneva institutions, the Swiss Institute of Bioinformatics and EPFL’s cancer and bioengineering research programs to develop the next generation of immune engineering technologies.
